Canada Markets closed

Medtronic plc (MDT)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
100.05+3.32 (+3.43%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close96.73
Open96.73
Bid99.53 x 800
Ask100.39 x 800
Day's Range96.60 - 100.09
52 Week Range72.13 - 122.15
Volume4,367,270
Avg. Volume5,679,826
Market Cap134.197B
Beta (5Y Monthly)0.68
PE Ratio (TTM)28.26
EPS (TTM)3.54
Earnings DateAug. 25, 2020
Forward Dividend & Yield2.32 (2.40%)
Ex-Dividend DateJun. 25, 2020
1y Target Est110.17
  • GlobeNewswire

    Medtronic Announces Comprehensive U.S. Launch of New InterStim™ Micro Neurostimulator

    First Patient Receives New Sacral Neuromodulation Device Implant at  Cleveland ClinicDUBLIN, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that its recently FDA-approved InterStim™ Micro neurostimulator for sacral neuromodulation (SNM) therapy is now available in the United States. Cleveland Clinic performed the first patient implant in the nation with the new device.Sacral neuromodulation sends electrical impulses to the sacral nerves located in the lower back to improve bladder and bowel control. Unlike oral medications that target the muscular component of bladder control, SNM offers control of symptoms through direct modulation of the nerve activity, normalizing the communication between the bladder and the brain.1,2"Effective long-term bladder and bowel control is needed for almost 55 million adults3,4,5,6 in the United States who often experience regular accidents and/or frequency issues that are associated with overactive bladder (OAB) and fecal incontinence (FI),” said Sandip Vasavada, M.D., professor at the Glickman Urological and Kidney Institute and section head Female Pelvic Medicine and Reconstructive Surgery, Cleveland Clinic. “A new FDA-approved option for these patients is a step forward.” Dr. Vasavada discloses compensation for speaker/trainer/educator activities.About InterStim Micro * At 2.8 cm3, it is 50% smaller than the market’s other rechargeable SNM device, making it the world’s smallest. * Allows patients to choose how and when they want to charge their device —from a quick charge once a week, or as infrequent as once per month, depending on the patient’s preference or device settings. * Features SureScan™ MRI technology, which enables full-body MRI conditional scans. * Does not require impedance checks prior to an MRI scan, providing more efficiency in patient care versus the other SNM system on the market. * Can recharge from zero to 100% in less than an hour, making it the fastest battery available. * Reduces the need for battery replacement surgeries due to its life of 15 years.“Patients unfortunately limit their lives socially, professionally and personally due to OAB and FI,” said Howard Goldman, M.D., professor and vice chairman of Quality and Patient Safety, Glickman Urological and Kidney Institute, Cleveland Clinic. “With this newly FDA-approved device, we have a new option and can offer more patients sacral neuromodulation therapy and improve their quality of life.” Dr. Goldman discloses compensation for speaker/trainer/educator and consulting activities.“OAB and FI patients want to live a life without limits, and we designed our new rechargeable SNM system to advance this reality,” said Brooke Story, vice president and general manager of the Pelvic Health& Gastric Therapies business, which is part of the Restorative Therapies Group at Medtronic. “We created our entire InterStim portfolio in partnership with physicians backed by a 25-year track record of experience in sacral neuromodulation including over 325,000 implanted patients, 5-year clinical data and more than 1,000 peer-reviewed articles. We are confident our InterStim systems give patients and physicians the best choice in SNM therapy.”About Medtronic Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world’s largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.-end- 1 Leng WW, Morrisroe SN. Sacral nerve stimulation for the overactive bladder. Urol Clin N Am. 2006;33:491-501.2 Kenefick NJ, Emmanuel A, Nicholls RJ. Effect of sacral nerve stimulation on autonomic nerve function. British Journal of Surgery. 2003;90:1256-1260.3 Stewart WF, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003 May;20(6):327-336.4 United Nations, Department of Economic and Social Affairs, Population Division (2011). World Population Prospects: The 2010 Revision, CD-ROM Edition.5 Whitehead WE, Borrud L, Goode PS, et al. Pelvic floor disorders network. Fecal incontinence in US adults: epidemiology and risk factors. Gastroenterology. 2009;137: 512-5176 United States Quick Facts. United States Census Bureau Web site. Available at: https://www.census.gov/quickfacts/table/ PST045215/00. Accessed July 19, 2016.  David T. Young Public Relations +1-774-284-2746Ryan Weispfenning Investor Relations +1-763-505-4626

  • GlobeNewswire

    Medtronic Expands Leadership in Treating Bladder and Bowel Control Conditions with Two New FDA-Approved Products: InterStim™ Micro Neurostimulator and InterStim™ SureScan™ MRI Leads

    * World’s Smallest Rechargeable Bladder/Bowel Control System — InterStim Micro — Features Trusted MRI Technology for Full-Body 1.5 and 3 Tesla MRI Scans  * Only Medtronic Offers Patients Personalized Therapy with the Choice of Rechargeable or Recharge-Free Sacral Neuromodulation Devices DUBLIN, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received approval from the United States Food and Drug Administration (FDA) for its InterStim™ Micro neurostimulator and InterStim™ SureScan™ MRI leads. InterStim Micro — the market’s smallest rechargeable device to deliver sacral neuromodulation (SNM) therapy — is used for treating overactive bladder (OAB), fecal incontinence (FI) and non-obstructive urinary retention. The InterStim SureScan MRI leads are used with InterStim Micro and with the recharge-free InterStim II, and allow full-body 1.5 and 3 Tesla MRI-conditional scans.1 The two new products make Medtronic the only company to offer patients and physicians a choice in SNM systems to match their preferences, lifestyle and treatment goals. Product is available for order immediately and will be delivered for patient procedures within days.“I’m excited about the new InterStim technology because it will allow so many more patients to be able to pursue SNM therapy and get back to living life their way,” said Dr. Steve Siegel, urologist at the Centers for Female Urology and Continence Care at Minnesota Urology. “The new technology by Medtronic allows me and my patients a choice between a rechargeable or a recharge-free system to best suit their lifestyle, and assures them they can have an MRI. Medtronic has left no box unchecked.”The new InterStim Micro: * Is 50% smaller than the market’s other rechargeable SNM device, making it the world’s smallest. * Allows patients to choose how and when they want to charge their device — from a quick charge once a week, or as infrequent as once per month, depending on the patient’s preference or device settings. * Features SureScan MRI technology, which does not require impedance checks prior to an MRI scan, providing more efficiency in patient care versus the other SNM system on the market. * Can recharge from zero to 100% in less than an hour, making it the fastest battery available. * Reduces the need for battery replacement surgeries due to its life of 15 years.SureScan™ MRI technology is a known and trusted brand by MRI technicians. Built on more than 19 years of full-body MRI research, 10 million simulated patient scans, and more than 1.2 million unique scanning scenarios, Medtronic SureScan™ MRI systems prioritize patient safety.1“The new InterStim portfolio brings the best choice in SNM therapy, offering MRI conditional recharge and recharge-free options for patients who have tried other therapies with little or no results,” said Brooke Story, vice president and general manager of the Pelvic Health & Gastric Therapies business, which is part of the Restorative Therapies Group at Medtronic. “We have the only five-year data for four indications to demonstrate the safety and efficacy of InterStim systems and 25 years’ experience in sacral neuromodulation therapy. We’re committed to partnering with physicians to bring life-enhancing technologies to patients.”Medtronic has seen rapid adoption of the new InterStim portfolio in Europe since receiving CE mark in January 2020. More than 37 million adults in the United States — almost one in six — suffer from overactive bladder (OAB),2,3 and nearly 18 million Americans — about one in 12 — have bowel incontinence.4,5 Many sufferers limit their lives socially, professionally, and personally.6 However, as many as 45% who suffer from symptoms do not seek treatment and as many as seven in 10 stop using medications within six months due to intolerable side effects or unsatisfying results.7-9 About Sacral Neuromodulation Sacral neuromodulation (SNM) uses a small device to send electrical impulses to the sacral nerves located in the lower back to improve bladder and bowel control. Unlike oral medications that target the muscular component of bladder control, SNM offers control of symptoms through direct modulation of the nerve activity, normalizing the communication between the bladder and the brain.10,11About Medtronic Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.-end- 1. Medtronic data on file. 2. Stewart WF, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003 May;20(6):327-336. 3. United Nations, Department of Economic and Social Affairs, Population Division (2011). World Population Prospects: The 2010 Revision, CD-ROM Edition. 4. Whitehead WE, Borrud L, Goode PS, et al. Pelvic floor disorders network. Fecal incontinence in US adults: epidemiology and risk factors. Gastroenterology. 2009;137: 512-517. 5. United States Quick Facts. United States Census Bureau Web site. Available at: https://www.census.gov/quickfacts/table/ PST045215/00. Accessed July 19, 2016. 6. Dmochowski RR, Newman DK. Impact of overactive bladder on women in the United States: results of a national survey. Current Medical Research and Opinion. 2007;23:65-76. 7. Leede Research, "Views on OAB: A Study for the National Association of Continence." December 16, 2015. 8. Yu YF, Nichol MB, Yu AP, et al. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California Medicaid Program. Value in Health. 2005;8(4)495-505. 9. Yeaw J, Benner JS, Walt JG, Sian S, Smith DB, et al. J Manag Care Pharm. 2009;15(9):728-740. 10. Leng WW, Morrisroe SN. Sacral nerve stimulation for the overactive bladder. Urol Clin N Am. 2006;33:491-501. 11. Kenefick NJ, Emmanuel A, Nicholls RJ. Effect of sacral nerve stimulation on autonomic nerve function. British Journal of Surgery. 2003;90:1256-1260. Katie Genereux Public Relations +1-763-514-0162Ryan Weispfenning Investor Relations +1-763-505-4626

  • Is Medtronic a Great Dividend Stock?
    Motley Fool

    Is Medtronic a Great Dividend Stock?

    If you're looking for a dividend stock to add to your portfolio, you know there are plenty of options out there. To do that, you'll need to consider not just the stock's current yield, but also its track record for increasing dividend payments and how safe those dividend payments are. Today, I'll look at whether medical device company Medtronic (NYSE: MDT) is a great dividend stock and whether you should consider adding it to your portfolio.